- AU$269.02m
- AU$255.45m
- NZ$69.07m
- 83
- 47
- 76
- 76
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 80.44 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.23 | ||
| Price to Tang. Book | 4.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.08% | ||
| Return on Equity | -8.05% | ||
| Operating Margin | -12.97% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NZ$m | 25.08 | 22.34 | 39.68 | 63.36 | 69.07 | 84.75 | 107.39 | 24.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.
Directors
- James McLean NEC
- Brian Ward CEO
- James Agnew CFO
- Simone Fircks VOP
- Brad Adams VPR
- Barnaby May VRD
- Tracy Weimar SEC
- Philip McCaw NED
- John Diddams NID
- Steven Engle NID (66)
- John Pinion NID (55)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- September 21st, 2007
- Public Since
- July 24th, 2020
- No. of Employees
- 261
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 344,900,256
- Address
- 64 Richard Pearse Drive, Mangere, AUCKLAND, 2022
- Web
- https://aroa.com/
- Phone
- +64 98693035
- Contact
- Simon Hinsley
- Auditors
- BDO Auckland
Upcoming Events for ARX
Similar to ARX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Atomo Diagnostics
Australian Stock Exchange - SEATS
FAQ
What is the Aroa Biosurgery share price?
As of Today at 18:20 UTC, shares in Aroa Biosurgery are trading at AU$0.78. This share price information is delayed by 15 minutes.
How has the Aroa Biosurgery share price performed this year?
Shares in Aroa Biosurgery last closed at AU$0.78 and the price had moved by over the past 365 days. In terms of relative price strength the Aroa Biosurgery share price has underperformed the ASX All Ordinaries Index by -9.44% over the past year.
What are the analyst and broker recommendations for Aroa Biosurgery?
The overall consensus recommendation for Aroa Biosurgery is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aroa Biosurgery dividend yield?
Aroa Biosurgery does not currently pay a dividend.
Does Aroa Biosurgery pay a dividend?
Aroa Biosurgery does not currently pay a dividend.
When does Aroa Biosurgery next pay dividends?
Aroa Biosurgery does not currently pay a dividend.
How do I buy Aroa Biosurgery shares?
To buy shares in Aroa Biosurgery you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aroa Biosurgery?
As of the previous close price of AU$0.78, shares in Aroa Biosurgery had a market capitalisation of AU$269.02m.
Where are Aroa Biosurgery shares listed?
Here are the trading details for Aroa Biosurgery:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ARX
What kind of share is Aroa Biosurgery?
Based on an overall assessment of its quality, value and momentum Aroa Biosurgery is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aroa Biosurgery share price forecast for 2025?
The analyst consensus target price for shares in Aroa Biosurgery is AU$0.94. That is 20.24% above the last closing price of AU$0.78.
Analysts covering Aroa Biosurgery currently have a consensus Earnings Per Share (EPS) forecast of -NZ$0.00 for the next financial year.
Find out moreWhat is the trend in the Aroa Biosurgery share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aroa Biosurgery. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +21.66%.
As of the last closing price of AU$0.78, shares in Aroa Biosurgery were trading +33.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aroa Biosurgery PE Ratio?
The Aroa Biosurgery PE ratio based on its reported earnings over the past 12 months is 80.44. The shares last closed at AU$0.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aroa Biosurgery?
Aroa Biosurgery's management team is headed by:
- James McLean - NEC
- Brian Ward - CEO
- James Agnew - CFO
- Simone Fircks - VOP
- Brad Adams - VPR
- Barnaby May - VRD
- Tracy Weimar - SEC
- Philip McCaw - NED
- John Diddams - NID
- Steven Engle - NID
- John Pinion - NID